Journal
MICROBIOLOGY AND IMMUNOLOGY
Volume 65, Issue 5, Pages 214-227Publisher
WILEY
DOI: 10.1111/1348-0421.12882
Keywords
intranasal vaccine; mouse; multi resistant Gram‐ negative; outer membrane vesicle; rapid vaccine prototyping
Categories
Funding
- Ludwig-Maximilians-Universitat Munchen
Ask authors/readers for more resources
Intranasal vaccination with outer membrane vesicles (OMV) from Escherichia coli strain CFT073 and three MDRGNO strains can induce strong humoral immune responses in mice, offering a potential rapid vaccine strategy to prevent infections caused by multi-drug resistant Gram-negative organisms (MDRGNO). Future studies should include challenge experiments and phase I trials in humans.
Hospital-acquired infections due to multi-drug resistant Gram-negative organisms (MDRGNO) pose a major threat to global health. A vaccine preventing colonization and consecutive infection with MDRGNO could be particularly valuable, as therapeutic options become increasingly limited. Outer membrane vesicles (OMV) of Escherichia coli strain CFT073 as well as three MDRGNO strains that had caused severe infections in humans were administered intranasally to mice, with and without cholera toxin as an adjuvant. The humoral immune responses were comparatively matched with the sera of patients, who had suffered an infection caused by the respective bacterium. Additionally, systemic and local toxicity was evaluated. Intranasal vaccination with OMV could elicit solid humoral immune responses (total IgM and IgG), specific for the respective MDRGNO in mice; decoration of vital bacterial membranes with antibodies was comparable to patients who had survived systemic infection with the respective bacterial isolate. After intranasal vaccination of mice with OMV no signs of local or systemic toxicity were observed. Intranasal vaccination with OMV may open up a rapid vaccine approach to prevent colonization and/or infection with pathogenic MDRGNOs, especially in an outbreak setting within a hospital. It may also be an option for patients who have to undergo elective interventions in centers with a high risk of infection for certain common MDRGNO. Future studies need to include challenge experiments as well as phase I trials in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available